Cystic Fibrosis Foundation – Therapeutics Development Award 2019
27/09/2019 09:01
Objetivo: The Cystic Fibrosis Foundation’s Therapeutics Development Award (TDA) program is designed to stimulate businesses to pursue novel therapies for cystic fibrosis by filling the gap between basic research and Phase 3 clinical trials. The program provides companies with funding and other resources to support studies that may include drug discovery; pre-clinical safety; pharmacokinetics/pharmacodynamics (PK/PD); and absorption, distribution, metabolism, and excretion (ADME) testing through early safety and efficacy trials in patients.
Inscrições: até 31 de outubro de 2019
Mais informações no site.
